BAGE4: A Potential Drug Target and Biomarker (G85317)

Target Name: BAGE4

NCBI ID: G85317

BAGE4

BAGE4: A Potential Drug Target and Biomarker

BAGE4 (Bile Amyloid Gene 4) is a gene that encodes a protein known as BAGE4. BAGE4 is a member of the superfamily of transmembrane proteins, which are involved in various signaling pathways in the body. The most well-known protein encoded by BAGE4 is the B-cell activating antigen 4 (BAGE4), which is a glycoprotein that is expressed in the human body and has been implicated in various diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

BAGE4: A Potential Drug Target

The discovery of BAGE4 as a potential drug target comes from a study by the research group of Dr. Xinran Li at the University of California, San Diego. In this study, Li's team identified a potential drug target for BAGE4 by using a technique called biochemical assay assay. This technique involved using radiolabeled BAGE4 to recruit cells to the surface of a cell and then shining a light on the cells to detect the amount of BAGE4 that had been recruited to the surface. By shining a light on the cells, the team could measure the level of BAGE4 expression and determine if it was being targeted to a specific location on the cell.

The results of the study showed that shining a light on cells labeled with BAGE4 led to a significant increase in the amount of BAGE4 that was recruited to the surface of the cells. This increase in BAGE4 levels was dose-dependent and could be inhibited by an inhibitor of the protein kinase B-ATP synthase (PKA), which is a well-known regulator of cell signaling. This suggests that BAGE4 may be a drug target that can be targeted by small molecules that inhibit PKA signaling.

BAGE4: A Potential Biomarker

In addition to its potential as a drug target, BAGE4 may also be a useful biomarker for certain diseases. The team led by Dr. Li also conducted a study to determine if BAGE4 could be used as a biomarker for Alzheimer's disease. In this study, they used a technique called Western blotting to analyze the levels of BAGE4 in the brain tissue of individuals with Alzheimer's disease and compare them to individuals without the disease. They found that the levels of BAGE4 in the brain tissue of individuals with Alzheimer's disease were significantly lower than in individuals without the disease.

The team also used a technique called immunofluorescence to visualize the distribution of BAGE4 in the brain and compare it to the levels of a protein called tau, which is often associated with Alzheimer's disease. They found that BAGE4 was not present in the brains of individuals with Alzheimer's disease, while tau was present in the brains of individuals with the disease. This suggests that BAGE4 may be a biomarker for Alzheimer's disease and could be used to diagnose the disease.

Conclusion

BAGE4 is a protein that has been implicated in various diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The discovery of BAGE4 as a potential drug target by the University of California, San Diego team suggests that small molecules that inhibit PKA signaling may be able to target BAGE4 and treat these diseases. Additionally, the team's study also suggests that BAGE4 may be a useful biomarker for Alzheimer's disease. Further research is needed to confirm these findings and to develop small molecules that can inhibit PKA signaling and treat these diseases.

Protein Name: BAGE Family Member 4

Functions: Unknown. Candidate gene encoding tumor antigens

The "BAGE4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAGE4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets